VP2-2024: Fuzuloparib with or without apatinib in HER2- metastatic breast cancer (mBC) patients (pts) with germline BRCA1/2 mutations (gBRCA1/2m): A randomized phase III trial
Titel:
VP2-2024: Fuzuloparib with or without apatinib in HER2- metastatic breast cancer (mBC) patients (pts) with germline BRCA1/2 mutations (gBRCA1/2m): A randomized phase III trial
Auteur:
Li, H. Liu, J. Liu, Y. Ouyang, Q. Wang, S. Tong, Z. Teng, Y. Sun, T. Wang, X. Cheng, J. Zhou, X. Fanfan, L. Yan, M. Nie, J. Ye, C. Shao, Z-M. Wang, Y. Yang, X. Song, E.